<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868149</url>
  </required_header>
  <id_info>
    <org_study_id>UW20-599</org_study_id>
    <nct_id>NCT04868149</nct_id>
  </id_info>
  <brief_title>Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS</brief_title>
  <official_title>Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a new&#xD;
      surgical procedure that induces rapid liver regeneration in patients with small liver remnant&#xD;
      planning for major liver resection. It is a two-staged operation with stage I including&#xD;
      portal vein ligation and splitting the right liver away from the left liver. After stage I,&#xD;
      the left liver will undergo rapid liver regeneration and the stage II operation can be&#xD;
      performed at 7-10 days after stage I operation when the liver remnant reaches an adequate&#xD;
      size. In stage II operation, the right liver that contains the tumor is then removed. This&#xD;
      surgical procedure was incepted in Germany in 2013 and was later started in Queen Mary&#xD;
      Hospital in Hong Kong for the first time in December 2015. The initial indication was mainly&#xD;
      for colorectal liver metastasis but due to the relatively high incidence of hepatocellular&#xD;
      carcinoma in Hong Kong, HBP surgery team of Queen Mary Hospital has transferred this&#xD;
      procedure to be applied for hepatitis-related hepatocellular carcinoma and so far, the centre&#xD;
      has cumulated one of the largest single-center experience in the literature. Nonetheless, the&#xD;
      usual approach for ALPPS involved open surgery and induced substantial surgical stress to the&#xD;
      patient, especially after stage I operation. With the advent of minimally invasive liver&#xD;
      surgery in recent years, the team has successfully applied laparoscopic surgery to ALPPS in&#xD;
      2019. Despite the advancement in laparoscopic surgical skills that rendered laparoscopic&#xD;
      ALPPS feasible, there is scarcity of data in the literature to evaluate its outcome in&#xD;
      comparison with open ALPPS with regard to perioperative recovery and liver regeneration.&#xD;
      Hence, the aim of this project is to evaluate the short-term clinical outcomes of&#xD;
      laparoscopic ALPPS and the impact of laparoscopy on liver remnant regeneration after ALPPS in&#xD;
      a prospective randomised clinical trial setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been&#xD;
      popularized as an alternative approach for FLR augmentation in recent years. The main&#xD;
      indication at the early phase of development of this procedure was bilobar colorectal liver&#xD;
      metastasis, or other non-primary liver tumors. Since 2015, HBP surgery team of Queen Mary&#xD;
      Hospital has started to transfer this novel approach to treat patients with hepatitis-related&#xD;
      hepatocellular carcinoma and small future liver remnant contemplating for major hepatectomy.&#xD;
      Despite the initial global enthusiasm to embark on ALPPS, the procedure was criticized for&#xD;
      its high postoperative morbidity and mortality rates. However, through the establishment of&#xD;
      the international ALPPS registry and familiarization of the procedure, the outcome of ALPPS&#xD;
      has been benchmarked and standardized with a mortality rate &lt;4%. The initial experience of&#xD;
      ALPPS for HCC was also reported. With cumulative experience, ALPPS has become a safe and&#xD;
      effective treatment approach for surgical modulation of insufficient FLR when compared with&#xD;
      the conventional approach in the form of portal vein embolization. Nonetheless, ALPPS is a&#xD;
      two-stage procedure that commonly involved an open laparotomy. However, the postoperative&#xD;
      pain control and speed of recovery after stage I ALPPS would be affected by the substantial&#xD;
      surgical stress induced by laparotomy. On the other hand, the rapid development of&#xD;
      laparoscopic surgery has rendered laparoscopic liver surgery a much more feasible and safer&#xD;
      surgical approach in recent years. As such, minimally invasive approach becomes an attractive&#xD;
      option for ALPPS, at least for stage I procedure. Data on the application of laparoscopic&#xD;
      ALPPS remained scarce with only one study reported the short-term outcome in a series of 10&#xD;
      patients predominantly affected by colorectal liver metastasis.&#xD;
&#xD;
      Since the short-term postoperative safety profile and underlying intraoperative haemodynamic&#xD;
      changes induced by ALPPS for hepatitis-related HCC under conventional open approach was&#xD;
      ascertained by our recent study, it is considered that it is the right time to introduce&#xD;
      laparoscopy for ALPPS and to compare its clinical outcome with open approach. To date, a&#xD;
      total of 4 patients have received laparoscopic ALPPS in the centre.&#xD;
&#xD;
      Recent studies suggested that laparoscopic liver resection may be associated with reduced&#xD;
      inflammatory and stress response as compared with open resection as indicated by a reduced&#xD;
      expression of inflammatory cytokines such as interleukin-6, tumor necrosis factor. On the&#xD;
      other hand, study on liver regeneration after open ALPPS showed an elevated gene expression&#xD;
      of IL-6 and TNF as well as increased plasma levels within 24 hours after the procedure when&#xD;
      compared with portal vein ligation. It remains uncertain if reduced level of cytokines or&#xD;
      inflammatory markers induced by laparoscopy would affect the liver regeneration rate in ALPPS&#xD;
      patients and its clinical outcome. Hence, there is a need to clarify this issue in the&#xD;
      current project.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patient are randomly assigned into either open or laparoscopic approach. The ratio of open and laparoscopic is 1:1.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of future liver remnant volume increment by percentage after stage I ALPPS</measure>
    <time_frame>During hospital stay after stage I ALPPS, an average of 1-2 weeks</time_frame>
    <description>Amount of future liver remnant volume increment by percentage after stage I ALPPS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preoperative blood loss during stage 1 ALPPS</measure>
    <time_frame>During hospital stay after stage I ALPPS, an average of 1-2 weeks</time_frame>
    <description>Preoperative blood loss during stage 1 ALPPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay after stage 1 ALPPS</measure>
    <time_frame>During hospital stay after stage I ALPPS, an average of 1-2 weeks</time_frame>
    <description>Length of hospital stay after stage 1 ALPPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity in number and mortality rates in percentage after stage 1 ALPPS</measure>
    <time_frame>During hospital stay after stage I ALPPS, an average of 1-2 weeks</time_frame>
    <description>Overall morbidity and mortality rates after stage 1 ALPPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS</measure>
    <time_frame>During hospital stay after stage I ALPPS, an average of 1-2 weeks</time_frame>
    <description>Inflammatory markers e.g. IL-6 (pg/ml), IL-8 (pg/ml) and TNF-alpha (pg/ml) associated with inflammation and regeneration after stage 1 ALPPS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Laparoscopic ALPPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic ALPPS procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open ALPPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open ALPPS procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)</intervention_name>
    <description>Surgery procedure</description>
    <arm_group_label>Laparoscopic ALPPS</arm_group_label>
    <arm_group_label>Open ALPPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of malignant liver tumor contemplating for extended right&#xD;
             hepatectomy or right trisectionectomy&#xD;
&#xD;
          2. Patient consent&#xD;
&#xD;
          3. Age &gt;/= 18&#xD;
&#xD;
          4. FLR/ESLV &lt;/= 30%&#xD;
&#xD;
          5. Indocyanine green clearance rate at 15 mins : &lt; 18%&#xD;
&#xD;
          6. Platelet count &gt; 100x10^9/L&#xD;
&#xD;
          7. Child A cirrhosis (due to hepatitis B/C virus, or alcohol, or autoimmune disease)&#xD;
&#xD;
          8. American Society of Anaesthesiology score &lt; 3&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
        Technical factors eligible for laparoscopic ALPPS&#xD;
&#xD;
          -  single long-segment portal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absence of consent&#xD;
&#xD;
          2. Decompensated liver disease as indicated by the presence of ascites, varices and&#xD;
             hepatic encephalopathy&#xD;
&#xD;
          3. ECOG performance status &gt;/= 3&#xD;
&#xD;
          4. Main portal vein thrombosis&#xD;
&#xD;
          5. FLR/ESLV &gt; 30%&#xD;
&#xD;
        Technical factors not eligible for laparoscopic ALPPS&#xD;
&#xD;
          -  Short-segment right portal vein or early bifurcation of right anterior/posterior&#xD;
             portal vein, or other portal vein anomalies&#xD;
&#xD;
          -  Large tumor size with diameter &gt; 5 cm&#xD;
&#xD;
          -  Intolerance to CO2 pneumoperitoneum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Chan</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Chan</last_name>
    <phone>+85222553025</phone>
    <email>acchan@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Crystal Kwan</last_name>
    <phone>+85222553635</phone>
    <email>cryskal@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Chan</last_name>
      <phone>+85222553025</phone>
      <email>acchan@hku.hk</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Kwan</last_name>
      <phone>+85222553635</phone>
      <email>cryskal@hku.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Albert Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Lang H, de Santibañes E, Schlitt HJ, Malagó M, van Gulik T, Machado MA, Jovine E, Heinrich S, Ettorre GM, Chan A, Hernandez-Alejandro R, Robles Campos R, Sandström P, Linecker M, Clavien PA. 10th Anniversary of ALPPS-Lessons Learned and quo Vadis. Ann Surg. 2019 Jan;269(1):114-119. doi: 10.1097/SLA.0000000000002797.</citation>
    <PMID>29727331</PMID>
  </reference>
  <results_reference>
    <citation>Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012 Mar;255(3):405-14. doi: 10.1097/SLA.0b013e31824856f5.</citation>
    <PMID>22330038</PMID>
  </results_reference>
  <results_reference>
    <citation>Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R, Soubrane O, Schnitzbauer AA, Raptis D, Tschuor C, Petrowsky H, De Santibanes E, Clavien PA; ALPPS Registry Group. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg. 2014 Nov;260(5):829-36; discussion 836-8. doi: 10.1097/SLA.0000000000000947.</citation>
    <PMID>25379854</PMID>
  </results_reference>
  <results_reference>
    <citation>Linecker M, Björnsson B, Stavrou GA, Oldhafer KJ, Lurje G, Neumann U, Adam R, Pruvot FR, Topp SA, Li J, Capobianco I, Nadalin S, Machado MA, Voskanyan S, Balci D, Hernandez-Alejandro R, Alvarez FA, De Santibañes E, Robles-Campos R, Malagó M, de Oliveira ML, Lesurtel M, Clavien PA, Petrowsky H. Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity. Ann Surg. 2017 Nov;266(5):779-786. doi: 10.1097/SLA.0000000000002446.</citation>
    <PMID>28806301</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan AC, Pang R, Poon RT. Simplifying the ALPPS procedure by the anterior approach. Ann Surg. 2014 Aug;260(2):e3. doi: 10.1097/SLA.0000000000000736.</citation>
    <PMID>24866543</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan AC, Poon RT, Chan C, Lo CM. Safety of ALPPS Procedure by the Anterior Approach for Hepatocellular Carcinoma. Ann Surg. 2016 Feb;263(2):e14-6. doi: 10.1097/SLA.0000000000001272.</citation>
    <PMID>26079914</PMID>
  </results_reference>
  <results_reference>
    <citation>Raptis DA, Linecker M, Kambakamba P, Tschuor C, Müller PC, Hadjittofi C, Stavrou GA, Fard-Aghaie MH, Tun-Abraham M, Ardiles V, Malagó M, Campos RR, Oldhafer KJ, Hernandez-Alejandro R, de Santibañes E, Machado MA, Petrowsky H, Clavien PA. Defining Benchmark Outcomes for ALPPS. Ann Surg. 2019 Nov;270(5):835-841. doi: 10.1097/SLA.0000000000003539.</citation>
    <PMID>31592812</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan A, Zhang WY, Chok K, Dai J, Ji R, Kwan C, Man N, Poon R, Lo CM. ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy. Ann Surg. 2021 May 1;273(5):957-965. doi: 10.1097/SLA.0000000000003433.</citation>
    <PMID>31305284</PMID>
  </results_reference>
  <results_reference>
    <citation>Machado MA, Makdissi FF, Surjan RC, Basseres T, Schadde E. Transition from open to laparoscopic ALPPS for patients with very small FLR: the initial experience. HPB (Oxford). 2017 Jan;19(1):59-66. doi: 10.1016/j.hpb.2016.10.004. Epub 2016 Nov 2.</citation>
    <PMID>27816312</PMID>
  </results_reference>
  <results_reference>
    <citation>Burpee SE, Kurian M, Murakame Y, Benevides S, Gagner M. The metabolic and immune response to laparoscopic versus open liver resection. Surg Endosc. 2002 Jun;16(6):899-904. Epub 2002 Feb 27.</citation>
    <PMID>12163951</PMID>
  </results_reference>
  <results_reference>
    <citation>Schlegel A, Lesurtel M, Melloul E, Limani P, Tschuor C, Graf R, Humar B, Clavien PA. ALPPS: from human to mice highlighting accelerated and novel mechanisms of liver regeneration. Ann Surg. 2014 Nov;260(5):839-46; discussion 846-7. doi: 10.1097/SLA.0000000000000949.</citation>
    <PMID>25379855</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Albert C.Y. Chan</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ALPPS</keyword>
  <keyword>Small future liver remnant</keyword>
  <keyword>Liver cancer</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Liver metastasis</keyword>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Minimal invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

